Why have studies of tailored anti-platelet therapy failed so far?SILLER-MATULA, Jolanta M; JILMA, Bernd.Thrombosis and haemostasis. 2013, Vol 110, Num 4, pp 628-631, issn 0340-6245, 4 p.Article

Bon usage des agents antiplaquettairesMT. Médecine thérapeutique. 2012, Vol 18, Num 4, pp 270-277, issn 1264-6520, 8 p.Article

Antiplatelet therapy in the perioperative periodENGELEN, S; SINNAEVE, P; VAN DAMME, H et al.Acta anaesthesiologica belgica. 2010, Vol 61, Num 3, pp 139-143, issn 0001-5164, 5 p.Conference Paper

Dyspnoea after antiplatelet agents : the AZD6140 controversySEREBRUANY, V. L; STEBBING, J; ATAR, D et al.International journal of clinical practice (Esher). 2007, Vol 61, Num 3, pp 529-533, issn 1368-5031, 5 p.Article

New antiplatelet agentsSAMAMA, M.Acta anaesthesiologica belgica. 2010, Vol 61, Num 3, issn 0001-5164, p. 127Conference Paper

Antiplatelet agents: Current drugs and future trendsMESSMORE, Harry L; JESKE, Walter P; WEHRMACHER, William et al.Hematology/oncology clinics of North America. 2005, Vol 19, Num 1, issn 0889-8588, vi, 87-117 [22 p.]Article

Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative PeriodHALL, Richard; MAZER, C. David.Anesthesia and analgesia. 2011, Vol 112, Num 2, pp 292-318, issn 0003-2999, 27 p.Article

Place des antiagrégants plaquettaires en cardiologieZAHRAOUI, Maria; ZOUIR, Imane; TAHIRI, A et al.Espérance médicale. 2005, Vol 12, Num 118, pp 375-378, 4 p.Article

Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' valueWALLENTIN, Lars; HIMMELMANN, Anders; STOREY, Robert F et al.Thrombosis and haemostasis. 2014, Vol 112, Num 1, pp 12-14, issn 0340-6245, 3 p.Article

Antiplatelet actions of 2-{4-[1-(2-chlorophenyl) piperazinyl]} methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one compoundYU-AN DING; TZ-CHONG CHOU; JI-WANG CHERN et al.Thrombosis research. 1995, Vol 77, Num 3, pp 291-303, issn 0049-3848Article

Antiagrégants plaquettaires: choix thérapeutique = Antiplatelet agents: therapeutic choiceMORIAU, M.Louvain médical. 1993, Vol 112, Num 4, pp 313-321, issn 0024-6956Conference Paper

Rationale for the development of antithrombotic, antimetastatic and fibrinolytic durgs: a mechanic point of view, international workshop, Montebello PQ, Canada, April 28-May 1, 1987BASTIDA, E. Ed; BUCHANAN, M. R; OFOSU, F. A et al.Seminars in thrombosis and hemostasis. 1988, Vol 14, Num 1, pp 1-132, issn 0094-6176Conference Proceedings

Bon usage des agents antiplaquettairesLa Revue de gériatrie. 2012, Vol 37, Num 8, pp 573-583, issn 0397-7927, 11 p.Article

Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 updateCUISSET, Thomas; VALGIMIGIL, Marco; MUDRA, Harald et al.EuroIntervention. 2010, Vol 6, Num 1, pp 39-45, issn 1774-024X, 7 p.Article

Variability of response to antiplatelet therapy : what should we do next?SHANTSILA, Eduard; LIP, Gregory Y. H.Fundamental & clinical pharmacology. 2009, Vol 23, Num 1, pp 19-22, issn 0767-3981, 4 p.Article

Antiplaquettaires et hémorragie peropératoire : Anesthésiologie = Antiplatelet drugs and intraoperative haemorrhageCHASSOT, Pierre-Guy; DELABAYS, Alain; RAVUSSIN, Patrick et al.Revue médicale suisse. 2006, Vol 2, Num 88, pp 2684-2687, issn 1660-9379, 4 p.Article

Les nouveaux médicaments antiplaquettaires = Antiplatelet new drugMONTALESCOT, G.Archives des maladies du coeur et des vaisseaux. Pratique. 1998, Num 72, pp 19-20, issn 1261-694XArticle

Klinische Pharmakologie von Acetylsalizylsäure = Clinical pharmacology of acetylsalicylic acidSCHRÖDER, H; SCHRÖR, K.Zeitschrift für Kardiologie. Supplementum. 1992, Vol 81, Num 4, pp 171-175, issn 0303-6308Conference Paper

Current antiplatelet options for NSTE-ACS patientsCAYLA, G; SILVAIN, J; O'CONNOR, S. A et al.QJM (Oxford. 1994. Print). 2012, Vol 105, Num 10, pp 935-948, issn 1460-2725, 14 p.Article

Les antiagrégants plaquettaires = Platelets antiagregatingFREIERMUTH, M.Lyon pharmaceutique. 1994, Vol 45, Num 7, pp 417-429, issn 0024-7804Article

Antiagrégants plaquettaires dans les autres pathologies = Platelet aggregation inhibitors in other pathologiesJOUVE, R.La Revue du praticien (Paris). 1989, Num 25, pp 2241-2243, issn 0035-2640, 3 p.Article

Antiaggregatorische und anticoagulante Eigenschaften von Oligoaminen. III: m-Phenylenbisaminoalkane = Inhibition de l'agrégation plaquettaire et effets anticoagulants des oligoamines. III: 1,3-phénylènebis(alkanamines) = Platelet aggregation inhibiting and anticoagulant effects of oligoamines. III: 1,3-Phenylenebis(alkylamine)REHSE, K; LÜKENS, U; LEISSRING, S et al.Archiv der Pharmazie (Weinheim). 1987, Vol 320, Num 3, pp 228-233, issn 0365-6233Article

Prasugrel development : Claims and achievementsSEREBRUANY, Victor; SHALITO, Inna; KOPYLEVA, Olga et al.Thrombosis and haemostasis. 2009, Vol 101, Num 1, pp 14-22, issn 0340-6245, 9 p.Article

Antiplatelet drugs in cardiovascular diseasesWESTON, C; RAO, U.International journal of clinical practice (Esher). 2003, Vol 57, Num 10, pp 898-905, issn 1368-5031, 8 p.Article

Novel antithrombotic drugs in developmentVERSTRAETE, M; ZOLDHELYI, P.Drugs (Basel). 1995, Vol 49, Num 6, pp 856-884, issn 0012-6667Article